Ren Chunzhen, Liu Kai, Zhao Xinke, Guo Huan, Luo Yali, Chang Juan, Gao Xiang, Lv Xinfang, Zhi Xiaodong, Wu Xue, Jiang Hugang, Chen Qilin, Li Yingdong
School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China.
Front Pharmacol. 2022 Jun 8;13:853289. doi: 10.3389/fphar.2022.853289. eCollection 2022.
Effective drugs for the treatment of myocardial fibrosis (MF) are lacking. Traditional Chinese medicine (TCM) has garnered increasing attention in recent years for the prevention and treatment of myocardial fibrosis. This Article describes the pathogenesis of myocardial fibrosis from the modern medicine, along with the research progress. Reports suggest that Chinese medicine may play a role in ameliorating myocardial fibrosis through different regulatory mechanisms such as reduction of inflammatory reaction and oxidative stress, inhibition of cardiac fibroblast activation, reduction in extracellular matrix, renin-angiotensin-aldosterone system regulation, transforming growth Factor-β1 (TGF-β1) expression downregulation, TGF-β1/Smad signalling pathway regulation, and microRNA expression regulation. Therefore, traditional Chinese medicine serves as a valuable source of candidate drugs for exploration of the mechanism of occurrence and development, along with clinical prevention and treatment of MF.
目前缺乏治疗心肌纤维化（MF）的有效药物。近年来，中药在心肌纤维化的防治方面日益受到关注。本文从现代医学角度阐述了心肌纤维化的发病机制及研究进展。报告表明，中药可能通过不同的调节机制发挥改善心肌纤维化的作用，如减轻炎症反应和氧化应激、抑制心脏成纤维细胞活化、减少细胞外基质、调节肾素-血管紧张素-醛固酮系统、下调转化生长因子-β1（TGF-β1）表达、调节TGF-β1/Smad信号通路以及调节微小RNA表达等。因此，中药是探索心肌纤维化发生发展机制以及临床防治的宝贵候选药物来源。
